查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药品市场：到2035年的行业趋势和全球预测 - 按药品类型、产品提供类型、可用​​性、电子药品平台类型、治疗领域、主要参与者和地区
市场调查报告书
商品编码
1534557

药品市场：到2035年的行业趋势和全球预测 - 按药品类型、产品提供类型、可用​​性、电子药品平台类型、治疗领域、主要参与者和地区

Pharmacy Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Pharmacy, Type of Product Offered, Availability, Type of e-pharmacy Platforms, Therapeutic Area, Key Players and Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 338 Pages | 商品交期: 最快1-2个工作天内

价格

药品市场规模估计在2024年达到 2.4 兆美元，并预计在2024-2035年预测期内年复合成长率为 5%。

根据美国卫生部的资料，大约 1.33亿美国人患有至少一种慢性病。为了解决这个问题，药局提供各种处方药、非处方药、医疗器材以及用于治疗的健康和保健产品。许多药局已成为 "一站式商店" ，除了传统的药房服务外，还提供各种产品。全球製药业转向个人化、永续发展和线上药局服务。药房采用自动化和数位化策略来提高效率、病患安全和个人化服务。

随着药局提供检测和疫苗接种服务，COVID-19 的爆发加速了产业成长。药剂师现在在社区药局提供额外的服务，例如葡萄糖测试、胆固醇测试和免疫接种。忠诚度计画在美国很受欢迎，到2022年，将有 33%的消费者参与新计画。到2022年，全球 57%的消费者将使用忠诚度积分来省钱。

在网路的高使用率和患者降低医疗成本的愿望的推动下，线上药局在全球范围内经历了快速成长。然而，这种成长也导致非法销售未经批准和错误识别的药品的增加。由于监管环境的差异，网路药局模式也有所不同，美国为处方药模式，欧洲为非处方药模式。随着产业的不断发展，药局采用微型配送中心等策略来支持处方药运输需求。向线上药房服务的转移，全球药品市场价值预计在预测期内将大幅成长。

本报告调查了全球药品市场，提供市场概况，及按药品类型、产品供应类型、可用​​性、药物类型、药物分子类型、电子药品平台类型、治疗领域、主要公司和地区划分的趋势，市场驱动因素和挑战等。

目录

第1章 背景

第2章 研究方法

第3章 经济与其他专案特定考量

第4章 执行摘要

第5章 简介

  • 製药业概览
  • 主要监理机构
  • 製药业的技术进步

第6章 市场影响分析、驱动因素、限制因素、机会、挑战

第7章 全球药品市场

第8章 药局市场（依药局类型）

第9章 药局市场（依提供的产品类型）

第10章 药局市场（依可用性）

第11章 药局市场（依药物类型）

第12章 药品市场（依药物分子类型）

第13章 药局市场（依电子药局平台类型）

第14章 药品市场（依治疗领域）

第15章 药品市场（依地区）

第16章 北美药局市场

第17章 欧洲药品市场

第18章 亚太药品市场

第19章 中东和北非医药市场

Product Code: RA100500

The Pharmacy Market is valued at USD 2.4 trillion in 2024 growing at a CAGR of 5% during the forecast period 2024-2035.

The latest research study delves into the pharmacy industry, examining trends, market analysis, competitive landscape, company competitiveness, value chain, market impact, and forecast opportunities. The increasing prevalence of chronic diseases and the aging population, combined with growing demand for home care, is driving the adoption of online pharmacy services. According to the US health department, approximately 133 million Americans suffer from at least one chronic disease. To address this, pharmacies are offering a wide range of prescription drugs, over-the-counter products, medical devices, and health and wellness products for treatment. Many pharmacies have become "one-stop-shops" offering a variety of products beyond traditional pharmacy services. The global pharmacy industry is shifting towards personalization, sustainability, and online pharmacy services. Pharmacies are adopting automation and digitalization strategies to enhance efficiency, patient safety, and personalized services. The COVID-19 pandemic has accelerated industry growth, with pharmacies offering testing and vaccination services. Pharmacists are now providing additional services like glucose testing, cholesterol screening, and immunizations in community pharmacies. Loyalty programs have become popular in the US, with 33% of consumers joining new programs in 2022. Globally, 57% of consumers used their loyalty points to save money in 2022.

Online pharmacies have experienced rapid growth worldwide, driven by high internet usage and patients' desire to reduce healthcare costs. However, the growth has also led to increased illegal sales of unapproved and misbranded drugs. Varying regulatory environments have resulted in different models of online pharmacies, with prescription-based models in the US and non-prescription models in Europe. As the industry continues to evolve, pharmacies are adopting strategies like micro-fulfillment centers to support prescription drug shipping demand. The shift towards online pharmacy services is expected to drive significant growth in the global pharmacy market value over the forecast period.

Key Market Segments

Type of Pharmacy

  • Retail Pharmacy
  • e-pharmacy
  • Hospital Pharmacy
  • Other Pharmacies

Type of Product Offered

  • Drugs / Pharmaceuticals
  • Medical Devices
  • Other Pharmacy Products

Availability

  • Prescription Products
  • Over-the-counter Products

Type of Drug

  • Branded / Patented Drugs
  • Generic Drugs

Type of Drug Molecule

  • Small Molecules
  • Biologics

Type of e-pharmacy Platform

  • App-based Platforms
  • Web-based Platforms

Therapeutic Area

  • Oncological Disorders
  • Cardiovascular Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Respiratory Disorders
  • Dermatological Disorders
  • Genetic Disorders
  • Autoimmune / Inflammatory Disorders
  • Other Disorders

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America

Market in North America

US

  • Canada
  • Rest of North America

Market in Europe

  • Germany
  • France
  • Italy

UK

  • Spain
  • Rest of Europe

Market in Asia-Pacific

  • Japan
  • China
  • India
  • Korea
  • Australia
  • New Zealand
  • Rest of Asia-Pacific

Market in Middle East and

North Africa

  • Egypt
  • Israel
  • Saudi Arabia
  • Rest of Middle East and North Africa

Market in Latin America

  • Brazil
  • Rest of Latin America

Research Coverage:

  • This report provides an overview provides a comprehensive look at the pharmacy industry, highlighting technological advancements. It highlights the involvement of the regulatory bodies, offering insights into the current state and future prospects of pharmacy domain.
  • This report offers a comprehensive analysis of several relevant factors influencing the growth of the market, including key drivers, restraints, emerging opportunities, and existing challenges, providing a detailed understanding of the market's dynamics and potential future trajectory.
  • This report provides a comprehensive estimate of the current pharmacy market value and its future growth potential over the next decade. Our analysis is based on multiple factors, including adoption trends and reliable secondary and primary data. We have also provided an informed forecast of the market's evolution during the forecast period, along with an assessment of the current and forecasted opportunity distribution within the pharmacy industry. To ensure robustness and account for future uncertainties, we have presented three forecast scenarios: conservative, base, and optimistic, representing different growth trajectories of the market.
  • Comprehensive projections of the current and future opportunity in the pharmacies market across different types of pharmacies, such as retail pharmacy, e-pharmacy, hospital pharmacy and other pharmacies.
  • Comprehensive projections of the current and future opportunity in the pharmacy market across different types of products offered, such as drugs / pharmaceuticals, medical devices and other pharmacy products.
  • The report provides detailed projections of the current and future market opportunity based on the availability, prescription and over-the-counter products in this domain.
  • Detailed projections of the current and future opportunity in the pharmacy industry across various types of drugs, such as branded / patented drugs and generic drugs.
  • Comprehensive projections of the current and future opportunity in the pharmacies market across different types of drug molecule, such as small molecules and biologics.
  • Comprehensive projections of the current and future opportunity in the pharmacy industry across various types of e-pharmacy platform, such as app-based and web-based platforms.
  • Comprehensive projections of the current and future opportunity in the pharmacy market based on therapeutic area, such as oncological disorders, cardiovascular disorders, neurological disorders, infectious diseases, metabolic disorders, respiratory disorders, dermatological disorders, genetic disorders, autoimmune / inflammatory disorders and other disorders.
  • Detailed predictions of the current and future opportunity for pharmacies across different geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.
  • Comprehensive predictions of the current and future opportunity in pharmacies market, based on type of pharmacy, product offered, availability and therapeutic area, across different countries, such as the US, Canada and rest of North America
  • Comprehensive projections of the current and future opportunity in pharmacy market, based on type of pharmacy, product offered, availability and therapeutic area, across different countries, such as Germany, France, Italy, the UK, Spain and rest of Europe.
  • The report provides detailed projections of the current and future market opportunity in the pharmacy industry, segmented by pharmacy type, product, availability, therapeutic area, and country, including Japan, China, India, Korea, Australia, New Zealand, and the rest of Asia-Pacific.
  • Comprehensive projections of the current and future opportunity in pharmacies market, based on type of pharmacy, product offered, availability and therapeutic area, across different countries, such as Egypt, Israel, Saudi Arabia and rest of Middle East and North Africa.
  • Comprehensive projections of the current and future opportunity in pharmacy market, on the basis of types of pharmacy, product offered, availability and therapeutic area, across different countries, such as Brazil and rest of Latin America.
  • Detailed projections of the current and future opportunity in the pharmacy industry across different key players.
  • The report provides a comprehensive overview of the current market landscape of leading pharmacies, including details on their year of establishment, company size, ownership structure, and geographical location of headquarters. This information is provided for each pharmacy, covering North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.
  • The report conducts a comprehensive analysis of the competitiveness of leading pharmacies, evaluating key factors such as company strength (years of experience), financial performance (annual revenues), and geographic presence (reach and ownership). This analysis provides valuable insights into the competitive landscape of the pharmacies market.
  • Comprehensive profiles of leading players in the pharmacy market. Each company profile features a brief overview of the company (including company's mission statement, year of establishment, number of employees, location of headquarters, business segments and leadership team), pharmacy related offerings, financial information and details related to its recent developments and an informed future outlook.
  • The report includes detailed profiles of prominent pharmacy players, featuring company overviews, including mission statements, establishment years, employee counts, headquarters locations, business segments, and executive team members, as well as their pharmacy offerings.

The report conducts a comprehensive value chain analysis, examining the pharmaceutical and medical device industries from raw material sourcing to patient delivery, identifying key stakeholders and opportunities for improvement to optimize profitability.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Pharmacy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Ahold Delhaize
  • Albertsons
  • A.S. Watson
  • Bestway
  • Cardinal Health
  • Cigna (Express Scripts)

COSMOS

  • Costco
  • CVS Health
  • Dirk Rossmann
  • Dr. Max
  • Good Neighbor Pharmacy
  • Health Mart
  • Kroger
  • Matsumoto Kiyoshi
  • Phoenix
  • Rite Aid
  • The Jean Coutu
  • Walmart
  • Walgreens Boots Alliance
  • Well Pharmacy

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating The Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. An Overview of Pharmacy Industry
  • 5.2. Key Regulatory Authorities
  • 5.3. Technological Advancements in Pharmacy Industry

6. MARKET IMPACT ANALYSIS, DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 6.1. Market Drivers
  • 6.2. Market Restraints
  • 6.3. Market Opportunities
  • 6.4. Market Challenges
  • 6.5. Conclusion

7. GLOBAL PHARMACY MARKET

  • 7.1. Assumptions and Methodology
  • 7.2. Global Pharmacy Market, till 2035
    • 7.2.1. Scenario Analysis
      • 7.2.1.1. Conservative Scenario
      • 7.2.1.2. Optimistic Scenario

8. PHARMACY MARKET, BY TYPE OF PHARMACY

  • 8.1. Pharmacy Market: Distribution by Type of Pharmacy, 2019, 2024 and 2035
    • 8.1.1. Pharmacy Market for Retail Pharmacy, till 2035
    • 8.1.2. Pharmacy Market for e-pharmacy, till 2035
    • 8.1.3. Pharmacy Market for Hospital Pharmacy, till 2035
    • 8.1.4. Pharmacy Market for Other Pharmacies, till 2035

9. PHARMACY MARKET, BY TYPE OF PRODUCT OFFERED

  • 9.1. Pharmacy Market: Distribution by Type of Product Offered, 2019, 2024 and 2035
    • 9.1.1. Pharmacy Market for Drugs / Pharmaceuticals, till 2035
    • 9.1.2. Pharmacy Market for Medical Devices, till 2035
    • 9.1.3. Pharmacy Market for Other Pharmacy Products, till 2035

10. PHARMACY MARKET, BY AVAILABILITY

  • 10.1. Pharmacy Market: Distribution by Availability, 2019, 2024 and 2035
    • 10.1.1. Pharmacy Market for Prescription Products, till 2035
    • 10.1.2. Pharmacy Market for Over-the-counter Products, till 2035

11. PHARMACY MARKET, BY TYPE OF DRUG

  • 11.1. Pharmacy Market: Distribution by Type of Drug, 2019, 2024 and 2035
    • 11.1.1. Pharmacy Market for Branded / Patented Drugs, till 2035
    • 11.1.2. Pharmacy Market for Generic Drugs, till 2035

12. PHARMACY MARKET, BY TYPE OF DRUG MOLECULE

  • 12.1. Pharmacy Market: Distribution by Type of Drug Molecule 2019, 2024 and 2035
    • 12.1.1. Pharmacy Market for Small Molecules, till 2035
    • 12.1.2. Pharmacy Market for Biologics, till 2035

13. PHARMACY MARKET, BY TYPE OF E-PHARMACY PLATFORM

  • 13.1. Pharmacy Market: Distribution by e-pharmacy Platforms, 2019, 2024 and 2035
    • 13.1.1. Pharmacy Market for App-based Platforms, till 2035
    • 13.1.2. Pharmacy Market for Web-based Platforms, till 2035

14. PHARMACY MARKET, BY THERAPEUTIC AREA

  • 14.1. Pharmacy Market: Distribution by Therapeutic Area, 2019, 2024 and 2035
    • 14.1.1. Pharmacy Market for Oncological Disorders, till 2035
    • 14.1.2. Pharmacy Market for Metabolic Disorders, till 2035
    • 14.1.3. Pharmacy Market for Autoimmune / Inflammatory Disorders, till 2035
    • 14.1.4. Pharmacy Market for Respiratory Disorders, till 2035
    • 14.1.5. Pharmacy Market for Infectious Diseases, till 2035
    • 14.1.6. Pharmacy Market for Cardiovascular Disorders, till 2035
    • 14.1.7. Pharmacy Market for Neurological Disorders, till 2035
    • 14.1.8. Pharmacy Market for Dermatological Disorders, till 2035
    • 14.1.9. Pharmacy Market for Genetic Disorders, till 2035
    • 14.1.10. Pharmacy Market for Other Disorders, till 2035

15. PHARMACY MARKET, BY GEOGRAPHICAL REGIONS

  • 15.1. Pharmacy Market: Distribution by Geographical Regions, 2019, 2024 and 2035
  • 15.2. Key Highlights from Distribution by Geographical Regions

16. PHARMACY MARKET IN NORTH AMERICA

  • 16.1. Pharmacy Market in North America, till 2035
    • 16.1.1. Pharmacy Market in the US, till 2035
      • 16.1.1.1. Pharmacy Market for Retail Pharmacy in the US, till 2035
      • 16.1.1.2. Pharmacy Market for e-pharmacy in the US, till 2035
      • 16.1.1.3. Pharmacy Market for Hospital Pharmacy in the US, till 2035
      • 16.1.1.4. Pharmacy Market for Other Pharmacies in the US, till 2035
      • 16.1.1.5. Pharmacy Market for Drugs / Pharmaceuticals in the US, till 2035
      • 16.1.1.6. Pharmacy Market for Medical Devices in the US, till 2035
      • 16.1.1.7. Pharmacy Market for Other Pharmacy Products in the US, till 2035
      • 16.1.1.8. Pharmacy Market for Prescription Products in the US, till 2035
      • 16.1.1.9. Pharmacy Market for Over-the-counter Products in the US, till 2035
      • 16.1.1.10. Pharmacy Market for Oncological Disorders in the US, till 2035
      • 16.1.1.11. Pharmacy Market for Metabolic Disorders in the US, till 2035
      • 16.1.1.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in the US, till 2035
      • 16.1.1.13. Pharmacy Market for Respiratory Disorders in the US, till 2035
      • 16.1.1.14. Pharmacy Market for Infectious Diseases in the US, till 2035
      • 16.1.1.15. Pharmacy Market for Cardiovascular Disorders in the US, till 2035
      • 16.1.1.16. Pharmacy Market for Neurological Disorders in the US, till 2035
      • 16.1.1.17. Pharmacy Market for Dermatological Disorders in the US, till 2035
      • 16.1.1.18. Pharmacy Market for Genetic Disorders in the US, till 2035
      • 16.1.1.19 Pharmacy Market for Other Disorders in the US, till 2035
    • 16.1.2. Pharmacy Market in Canada, till 2035
      • 16.1.2.1. Pharmacy Market for Retail Pharmacy in Canada, till 2035
      • 16.1.2.2. Pharmacy Market for e-pharmacy in Canada, till 2035
      • 16.1.2.3. Pharmacy Market for Hospital Pharmacy in Canada, till 2035
      • 16.1.2.4. Pharmacy Market for Other Pharmacies in Canada, till 2035
      • 16.1.2.5. Pharmacy Market for Drugs / Pharmaceuticals in Canada, till 2035
      • 16.1.2.6. Pharmacy Market for Medical Devices in Canada, till 2035
      • 16.1.2.7. Pharmacy Market for Other Pharmacy Products in Canada, till 2035
      • 16.1.2.8. Pharmacy Market for Prescription Products in Canada, till 2035
      • 16.1.2.9. Pharmacy Market for Over-the-counter Products in Canada, till 2035
      • 16.1.2.10. Pharmacy Market for Oncological Disorders in Canada, till 2035
      • 16.1.2.11. Pharmacy Market for Metabolic Disorders in Canada, till 2035
      • 16.1.2.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Canada, till 2035
      • 16.1.2.13. Pharmacy Market for Respiratory Disorders in Canada, till 2035
      • 16.1.2.14. Pharmacy Market for Infectious Diseases in Canada, till 2035
      • 16.1.2.15. Pharmacy Market for Cardiovascular Disorders in Canada, till 2035
      • 16.1.2.16. Pharmacy Market for Neurological Disorders in Canada, till 2035
      • 16.1.2.17. Pharmacy Market for Dermatological Disorders in Canada, till 2035
      • 16.1.2.18. Pharmacy Market for Genetic Disorders in Canada, till 2035
      • 16.1.2.19 Pharmacy Market for Other Disorders in Canada, till 2035
    • 16.1.3. Pharmacy Market in Rest of North America, till 2035
      • 16.1.3.1. Pharmacy Market for Retail Pharmacy in Rest of North America, till 2035
      • 16.1.3.2. Pharmacy Market for e-pharmacy in Rest of North America, till 2035
      • 16.1.3.3. Pharmacy Market for Hospital Pharmacy in Rest of North America, till 2035
      • 16.1.3.4. Pharmacy Market for Other Pharmacies in Rest of North America, till 2035
      • 16.1.3.5. Pharmacy Market for Drugs / Pharmaceuticals in Rest of North America, till 2035
      • 16.1.3.6. Pharmacy Market for Medical Devices in Rest of North America, till 2035
      • 16.1.3.7. Pharmacy Market for Other Pharmacy Products in Rest of North America, till 2035
      • 16.1.3.8. Pharmacy Market for Prescription Products in Rest of North America, till 2035
      • 16.1.3.9. Pharmacy Market for Over-the-counter Products in Rest of North America, till 2035
      • 16.1.3.10. Pharmacy Market for Oncological Disorders in Rest of North America, till 2035
      • 16.1.3.11. Pharmacy Market for Metabolic Disorders in Rest of North America, till 2035
      • 16.1.3.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Rest of North America, till 2035
      • 16.1.3.13. Pharmacy Market for Respiratory Disorders in Rest of North America, till 2035
      • 16.1.3.14. Pharmacy Market for Infectious Diseases in Rest of North America, till 2035
      • 16.1.3.15. Pharmacy Market for Cardiovascular Disorders in Rest of North America, till 2035
      • 16.1.3.16. Pharmacy Market for Neurological Disorders in Rest of North America, till 2035
      • 16.1.3.17. Pharmacy Market for Dermatological Disorders in Rest of North America, till 2035
      • 16.1.3.18. Pharmacy Market for Genetic Disorders in Rest of North America, till 2035
      • 16.1.3.19 Pharmacy Market for Other Disorders in Rest of North America, till 2035

17. PHARMACY MARKET IN EUROPE

  • 17.1. Pharmacy Market in Europe, till 2035
    • 17.1.1. Pharmacy Market in Germany, till 2035
      • 17.1.1.1. Pharmacy Market for Retail Pharmacy in Germany, till 2035
      • 17.1.1.2. Pharmacy Market for e-pharmacy in Germany, till 2035
      • 17.1.1.3. Pharmacy Market for Hospital Pharmacy in Germany, till 2035
      • 17.1.1.4. Pharmacy Market for Other Pharmacies in Germany, till 2035
      • 17.1.1.5. Pharmacy Market for Drugs / Pharmaceuticals in Germany, till 2035
      • 17.1.1.6. Pharmacy Market for Medical Devices in Germany, till 2035
      • 17.1.1.7. Pharmacy Market for Other Pharmacy Products in Germany, till 2035
      • 17.1.1.8. Pharmacy Market for Prescription Products in Germany, till 2035
      • 17.1.1.9. Pharmacy Market for Over-the-counter Products in Germany, till 2035
      • 17.1.1.10. Pharmacy Market for Oncological Disorders in Germany, till 2035
      • 17.1.1.11. Pharmacy Market for Metabolic Disorders in Germany, till 2035
      • 17.1.1.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Germany, till 2035
      • 17.1.1.13. Pharmacy Market for Respiratory Disorders in Germany, till 2035
      • 17.1.1.14. Pharmacy Market for Infectious Diseases in Germany, till 2035
      • 17.1.1.15. Pharmacy Market for Cardiovascular Disorders in Germany, till 2035
      • 17.1.1.16. Pharmacy Market for Neurological Disorders in Germany, till 2035
      • 17.1.1.17. Pharmacy Market for Dermatological Disorders in Germany, till 2035
      • 17.1.1.18. Pharmacy Market for Genetic Disorders in Germany, till 2035
      • 17.1.1.19 Pharmacy Market for Other Disorders in Germany, till 2035
    • 17.1.2. Pharmacy Market in France, till 2035
      • 17.1.2.1. Pharmacy Market for Retail Pharmacy in France, till 2035
      • 17.1.2.2. Pharmacy Market for e-pharmacy in France, Till 2035
      • 17.1.2.3. Pharmacy Market for Hospital Pharmacy in France, till 2035
      • 17.1.2.4. Pharmacy Market for Other Pharmacies in France, till 2035
      • 17.1.2.5. Pharmacy Market for Drugs / Pharmaceuticals in France, till 2035
      • 17.1.2.6. Pharmacy Market for Medical Devices in France, till 2035
      • 17.1.2.7. Pharmacy Market for Other Pharmacy Products in France, till 2035
      • 17.1.2.8. Pharmacy Market for Prescription Products in France, till 2035
      • 17.1.2.9. Pharmacy Market for Over-the-counter Products in France, till 2035
      • 17.1.2.10. Pharmacy Market for Oncological Disorders in France, till 2035
      • 17.1.2.11. Pharmacy Market for Metabolic Disorders in France, till 2035
      • 17.1.2.12. Autoimmune / Inflammatory Disorders in France, till 2035
      • 17.1.2.13. Pharmacy Market for Respiratory Disorders in France, till 2035
      • 17.1.2.14. Pharmacy Market for Infectious Diseases in France, till 2035
      • 17.1.2.15. Pharmacy Market for Cardiovascular Disorders in France, till 2035
      • 17.1.2.16. Pharmacy Market for Neurological Disorders in France, till 2035
      • 17.1.2.17. Pharmacy Market for Dermatological Disorders in France, till 2035
      • 17.1.2.18. Pharmacy Market for Genetic Disorders in France, till 2035
      • 17.1.2.19 Pharmacy Market for Other Disorders in France, till 2035
    • 17.1.3. Pharmacy Market in Italy, till 2035
      • 17.1.3.1. Pharmacy Market for Retail Pharmacy in Italy, till 2035
      • 17.1.3.2. Pharmacy Market for e-pharmacy in Italy, till 2035
      • 17.1.3.3. Pharmacy Market for Hospital Pharmacy in Italy, till 2035
      • 17.1.3.4. Pharmacy Market for Other Pharmacies in Italy, till 2035
      • 17.1.3.5. Pharmacy Market for Drugs / Pharmaceuticals in Italy, till 2035
      • 17.1.3.6. Pharmacy Market for Medical Devices in Italy, till 2035
      • 17.1.3.7. Pharmacy Market for Other Pharmacy Products in Italy, till 2035
      • 17.1.3.8. Pharmacy Market for Prescription Products in Italy, till 2035
      • 17.1.3.9. Pharmacy Market for Over-the-counter Products in Italy, till 2035
      • 17.1.3.10. Pharmacy Market for Oncological Disorders in Italy, till 2035
      • 17.1.3.11. Pharmacy Market for Metabolic Disorders in Italy, till 2035
      • 17.1.3.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Italy, till 2035
      • 17.1.3.13. Pharmacy Market for Respiratory Disorders in Italy, till 2035
      • 17.1.3.14. Pharmacy Market for Infectious Diseases in Italy, till 2035
      • 17.1.3.15. Pharmacy Market for Cardiovascular Disorders in Italy, till 2035
      • 17.1.3.16. Pharmacy Market for Neurological Disorders in Italy, till 2035
      • 17.1.3.17. Pharmacy Market for Dermatological Disorders in Italy, till 2035
      • 17.1.3.18. Pharmacy Market for Genetic Disorders in Italy, till 2035
      • 17.1.3.19 Pharmacy Market for Other Disorders in Italy, till 2035
    • 17.1.4. Pharmacy Market in the UK, till 2035
      • 17.1.4.1. Pharmacy Market for Retail Pharmacy in the UK, till 2035
      • 17.1.4.2. Pharmacy Market for e-pharmacy in the UK, till 2035
      • 17.1.4.3. Pharmacy Market for Hospital Pharmacy in the UK, till 2035
      • 17.1.4.4. Pharmacy Market for Other Pharmacies in the UK, till 2035
      • 17.1.4.5. Pharmacy Market for Drugs / Pharmaceuticals in the UK, till 2035
      • 17.1.4.6. Pharmacy Market for Medical Devices in the UK, till 2035
      • 17.1.4.7. Pharmacy Market for Other Pharmacy Products in the UK, till 2035
      • 17.1.4.8. Pharmacy Market for Prescription Products in the UK, till 2035
      • 17.1.4.9. Pharmacy Market for Over-the-counter Products in the UK, till 2035
      • 17.1.4.10. Pharmacy Market for Oncological Disorders in the UK, till 2035
      • 17.1.4.11. Pharmacy Market for Metabolic Disorders in the UK, till 2035
      • 17.1.4.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in the UK, till 2035
      • 17.1.4.13. Pharmacy Market for Respiratory Disorders in the UK, till 2035
      • 17.1.4.14. Pharmacy Market for Infectious Diseases in the UK, till 2035
      • 17.1.4.15. Pharmacy Market for Cardiovascular Disorders in the UK, till 2035
      • 17.1.4.16. Pharmacy Market for Neurological Disorders in the UK, till 2035
      • 17.1.4.17. Pharmacy Market for Dermatological Disorders in the UK, till 2035
      • 17.1.4.18. Pharmacy Market for Genetic Disorders in the UK, till 2035
      • 17.1.4.19 Pharmacy Market for Other Disorders in the UK, till 2035
    • 17.1.5. Pharmacy Market in Spain, till 2035
      • 17.1.5.1. Pharmacy Market for Retail Pharmacy in Spain, till 2035
      • 17.1.5.2. Pharmacy Market for e-pharmacy in Spain, till 2035
      • 17.1.5.3. Pharmacy Market for Hospital Pharmacy in Spain, till 2035
      • 17.1.5.4. Pharmacy Market for Other Pharmacies in Spain, till 2035
      • 17.1.5.5. Pharmacy Market for Drugs / Pharmaceuticals in Spain, till 2035
      • 17.1.5.6. Pharmacy Market for Medical Devices in Spain, till 2035
      • 17.1.5.7. Pharmacy Market for Other Pharmacy Products in Spain, till 2035
      • 17.1.5.8. Pharmacy Market for Prescription Products in Spain, till 2035
      • 17.1.5.9. Pharmacy Market for Over-the-counter Products in Spain, till 2035
      • 17.1.5.10. Pharmacy Market for Oncological Disorders in Spain, till 2035
      • 17.1.5.11. Pharmacy Market for Metabolic Disorders in Spain, till 2035
      • 17.1.5.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Spain, till 2035
      • 17.1.5.13. Pharmacy Market for Respiratory Disorders in Spain, till 2035
      • 17.1.5.14. Pharmacy Market for Infectious Diseases in Spain, till 2035
      • 17.1.5.15. Pharmacy Market for Cardiovascular Disorders in Spain, till 2035
      • 17.1.5.16. Pharmacy Market for Neurological Disorders in Spain, till 2035
      • 17.1.5.17. Pharmacy Market for Dermatological Disorders in Spain, till 2035
      • 17.1.5.18. Pharmacy Market for Genetic Disorders in Spain, till 2035
      • 17.1.5.19 Pharmacy Market for Other Disorders in Spain, till 2035
    • 17.1.6. Pharmacy Market in Rest of Europe, till 2035
      • 17.1.6.1. Pharmacy Market for Retail Pharmacy in Rest of Europe, till 2035
      • 17.1.6.2. Pharmacy Market for e-pharmacy in Rest of Europe, till 2035
      • 17.1.6.3. Pharmacy Market for Hospital Pharmacy in Rest of Europe, till 2035
      • 17.1.6.4. Pharmacy Market for Other Pharmacies in Rest of Europe, till 2035
      • 17.1.6.5. Pharmacy Market for Drugs / Pharmaceuticals in Rest of Europe, till 2035
      • 17.1.6.6. Pharmacy Market for Medical Devices in Rest of Europe, till 2035
      • 17.1.6.7. Pharmacy Market for Other Pharmacy Products in Rest of Europe, till 2035
      • 17.1.6.8. Pharmacy Market for Prescription Products in Rest of Europe, till 2035
      • 17.1.6.9. Pharmacy Market for Over-the-counter Products in Rest of Europe, till 2035
      • 17.1.6.10. Pharmacy Market for Oncological Disorders in Rest of Europe, till 2035
      • 17.1.6.11. Pharmacy Market for Metabolic Disorders in Rest of Europe, till 2035
      • 17.1.6.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Rest of Europe, till 2035
      • 17.1.6.13. Pharmacy Market for Respiratory Disorders in Rest of Europe, till 2035
      • 17.1.6.14. Pharmacy Market for Infectious Diseases in Rest of Europe, till 2035
      • 17.1.6.15. Pharmacy Market for Cardiovascular Disorders in Rest of Europe, till 2035
      • 17.1.6.16. Pharmacy Market for Neurological Disorders in Rest of Europe, till 2035
      • 17.1.6.17. Pharmacy Market for Dermatological Disorders in Rest of Europe, till 2035
      • 17.1.6.18. Pharmacy Market for Genetic Disorders in Rest of Europe, till 2035
      • 17.1.6.19 Pharmacy Market for Other Disorders in Rest of Europe, till 2035

18. PHARMACY MARKET IN ASIA-PACIFIC

  • 18.1. Pharmacy Market in Asia-Pacific, till 2035
    • 18.1.1. Pharmacy Market in Japan, till 2035
      • 18.1.1.1. Pharmacy Market for Retail Pharmacy in Japan, till 2035
      • 18.1.1.2. Pharmacy Market for e-pharmacy in Japan, till 2035
      • 18.1.1.3. Pharmacy Market for Hospital Pharmacy in Japan, till 2035
      • 18.1.1.4. Pharmacy Market for Other Pharmacies in Japan, till 2035
      • 18.1.1.5. Pharmacy Market for Drugs / Pharmaceuticals in Japan, till 2035
      • 18.1.1.6. Pharmacy Market for Medical Devices in Japan, till 2035
      • 18.1.1.7. Pharmacy Market for Other Pharmacy Products in Japan, till 2035
      • 18.1.1.8. Pharmacy Market for Prescription Products in Japan, till 2035
      • 18.1.1.9. Pharmacy Market for Over-the-counter Products in Japan, till 2035
      • 18.1.1.10. Pharmacy Market for Oncological Disorders in Japan, till 2035
      • 18.1.1.11. Pharmacy Market for Metabolic Disorders in Japan, till 2035
      • 18.1.1.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Japan, till 2035
      • 18.1.1.13. Pharmacy Market for Respiratory Disorders in Japan, till 2035
      • 18.1.1.14. Pharmacy Market for Infectious Diseases in Japan, till 2035
      • 18.1.1.15. Pharmacy Market for Cardiovascular Disorders in Japan, till 2035
      • 18.1.1.16. Pharmacy Market for Neurological Disorders in Japan, till 2035
      • 18.1.1.17. Pharmacy Market for Dermatological Disorders in Japan, till 2035
      • 18.1.1.18. Pharmacy Market for Genetic Disorders in Japan, till 2035
      • 18.1.1.19. Pharmacy Market for Other Disorders in Japan, till 2035
    • 18.1.2. Pharmacy Market in China, till 2035
      • 18.1.2.1. Pharmacy Market for Retail Pharmacy in China, till 2035
      • 18.1.2.2. Pharmacy Market for e-pharmacy in China, till 2035
      • 18.1.2.3. Pharmacy Market for Hospital Pharmacy in China, till 2035
      • 18.1.2.4. Pharmacy Market for Other Pharmacies in China, till 2035
      • 18.1.2.5. Pharmacy Market for Drugs / Pharmaceuticals in China, till 2035
      • 18.1.2.6. Pharmacy Market for Medical Devices in China, till 2035
      • 18.1.2.7. Pharmacy Market for Other Pharmacy Products in China, till 2035
      • 18.1.2.8. Pharmacy Market for Prescription Products in China, till 2035
      • 18.1.2.9. Pharmacy Market for Over-the-counter Products in China, till 2035
      • 18.1.2.10. Pharmacy Market for Oncological Disorders in China, till 2035
      • 18.1.2.11. Pharmacy Market for Metabolic Disorders in China, till 2035
      • 18.1.2.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in China, till 2035
      • 18.1.2.13. Pharmacy Market for Respiratory Disorders in China, till 2035
      • 18.1.2.14. Pharmacy Market for Infectious Diseases in China, till 2035
      • 18.1.2.15. Pharmacy Market for Cardiovascular Disorders in China, till 2035
      • 18.1.2.16. Pharmacy Market for Neurological Disorders in China, till 2035
      • 18.1.2.17. Pharmacy Market for Dermatological Disorders in China, till 2035
      • 18.1.2.18. Pharmacy Market for Genetic Disorders in China, till 2035
      • 18.1.2.19. Pharmacy Market for Other Disorders in China, till 2035
    • 18.1.3. Pharmacy Market in India, till 2035
      • 18.1.3.1. Pharmacy Market for Retail Pharmacy in India, till 2035
      • 18.1.3.2. Pharmacy Market for e-pharmacy in India, till 2035
      • 18.1.3.3. Pharmacy Market for Hospital Pharmacy in India, till 2035
      • 18.1.3.4. Pharmacy Market for Other Pharmacies in India, till 2035
      • 18.1.3.5. Pharmacy Market for Drugs / Pharmaceuticals in India, till 2035
      • 18.1.3.6. Pharmacy Market for Medical Devices in India, till 2035
      • 18.1.3.7. Pharmacy Market for Other Pharmacy Products in India, till 2035
      • 18.1.3.8. Pharmacy Market for Prescription Products in India, till 2035
      • 18.1.3.9. Pharmacy Market for Over-the-counter Products in India, till 2035
      • 18.1.3.10. Pharmacy Market for Oncological Disorders in India, till 2035
      • 18.1.3.11. Pharmacy Market for Metabolic Disorders in India, till 2035
      • 18.1.3.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in India, till 2035
      • 18.1.3.13. Pharmacy Market for Respiratory Disorders in India, till 2035
      • 18.1.3.14. Pharmacy Market for Infectious Diseases in India, till 2035
      • 18.1.3.15. Pharmacy Market for Cardiovascular Disorders in India, till 2035
      • 18.1.3.16. Pharmacy Market for Neurological Disorders in India, till 2035
      • 18.1.3.17. Pharmacy Market for Dermatological Disorders in India, till 2035
      • 18.1.3.18. Pharmacy Market for Genetic Disorders in India, till 2035
      • 18.1.3.19. Pharmacy Market for Other Disorders in India, till 2035
    • 18.3.4. Pharmacy Market in Korea, till 2035
      • 18.1.4.1. Pharmacy Market for Retail Pharmacy in Korea, till 2035
      • 18.1.4.2. Pharmacy Market for e-pharmacy in Korea, till 2035
      • 18.1.4.3. Pharmacy Market for Hospital Pharmacy in Korea, till 2035
      • 18.1.4.4. Pharmacy Market for Other Pharmacies in Korea, till 2035
      • 18.1.4.5. Pharmacy Market for Drugs / Pharmaceuticals in Korea, till 2035
      • 18.1.4.6. Pharmacy Market for Medical Devices in Korea, till 2035
      • 18.1.4.7. Pharmacy Market for Other Pharmacy Products in Korea, till 2035
      • 18.1.4.8. Pharmacy Market for Prescription Products in Korea, till 2035
      • 18.1.4.9. Pharmacy Market for Over-the-counter Products in Korea, till 2035
      • 18.1.4.10. Pharmacy Market for Oncological Disorders in Korea, till 2035
      • 18.1.4.11. Pharmacy Market for Metabolic Disorders in Korea, till 2035
      • 18.1.4.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Korea, till 2035
      • 18.1.4.13. Pharmacy Market for Respiratory Disorders in Korea, till 2035
      • 18.1.4.14. Pharmacy Market for Infectious Diseases in Korea, till 2035
      • 18.1.4.15. Pharmacy Market for Cardiovascular Disorders in Korea, till 2035
      • 18.1.4.16. Pharmacy Market for Neurological Disorders in Korea, till 2035
      • 18.1.4.17. Pharmacy Market for Dermatological Disorders in Korea, till 2035
      • 18.1.4.18. Pharmacy Market for Genetic Disorders in Korea, till 2035
      • 18.1.4.19. Pharmacy Market for Other Disorders in Korea, till 2035
    • 18.1.5. Pharmacy Market in Australia, till 2035
      • 18.1.5.1. Pharmacy Market for Retail Pharmacy in Australia, till 2035
      • 18.1.5.2. Pharmacy Market for e-pharmacy in Australia, till 2035
      • 18.1.5.3. Pharmacy Market for Hospital Pharmacy in Australia, till 2035
      • 18.1.5.4. Pharmacy Market for Other Pharmacies in Australia, till 2035
      • 18.1.5.5. Pharmacy Market for Drugs / Pharmaceuticals in Australia, till 2035
      • 18.1.5.6. Pharmacy Market for Medical Devices in Australia, till 2035
      • 18.1.5.7. Pharmacy Market for Other Pharmacy Products in Australia, till 2035
      • 18.1.5.8. Pharmacy Market for Prescription Products in Australia, till 2035
      • 18.1.5.9. Pharmacy Market for Over-the-counter Products in Australia, till 2035
      • 18.1.5.10. Pharmacy Market for Oncological Disorders in Australia, till 2035
      • 18.1.5.11. Pharmacy Market for Metabolic Disorders in Australia, till 2035
      • 18.1.5.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Australia, till 2035
      • 18.1.5.13. Pharmacy Market for Respiratory Disorders in Australia, till 2035
      • 18.1.5.14. Pharmacy Market for Infectious Diseases in Australia, till 2035
      • 18.1.5.15. Pharmacy Market for Cardiovascular Disorders in Australia, till 2035
      • 18.1.5.16. Pharmacy Market for Neurological Disorders in Australia, till 2035
      • 18.1.5.17. Pharmacy Market for Dermatological Disorders in Australia, till 2035
      • 18.1.5.18. Pharmacy Market for Genetic Disorders in Australia, till 2035
      • 18.1.5.19. Pharmacy Market for Other Disorders in Australia, till 2035
    • 18.1.6. Pharmacy Market in New Zealand, till 2035
      • 18.1.6.1. Pharmacy Market for Retail Pharmacy in New Zealand, till 2035
      • 18.1.6.2. Pharmacy Market for e-pharmacy in New Zealand, till 2035
      • 18.1.6.3. Pharmacy Market for Hospital Pharmacy in New Zealand, till 2035
      • 18.1.6.4. Pharmacy Market for Other Pharmacies in New Zealand, till 2035
      • 18.1.6.5. Pharmacy Market for Drugs / Pharmaceuticals in New Zealand, till 2035
      • 18.1.6.6. Pharmacy Market for Medical Devices in New Zealand, till 2035
      • 18.1.6.7. Pharmacy Market for Other Pharmacy Products in New Zealand, till 2035
      • 18.1.6.8. Pharmacy Market for Prescription Products in New Zealand, till 2035
      • 18.1.6.9. Pharmacy Market for Over-the-counter Products in New Zealand, till 2035
      • 18.1.6.10. Pharmacy Market for Oncological Disorders in New Zealand, till 2035
      • 18.1.6.11. Pharmacy Market for Metabolic Disorders in New Zealand, till 2035
      • 18.1.6.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in New Zealand, till 2035
      • 18.1.6.13. Pharmacy Market for Respiratory Disorders in New Zealand, till 2035
      • 18.1.6.14. Pharmacy Market for Infectious Diseases in New Zealand, till 2035
      • 18.1.6.15. Pharmacy Market for Cardiovascular Disorders in New Zealand, till 2035
      • 18.1.6.16. Pharmacy Market for Neurological Disorders in New Zealand, till 2035
      • 18.1.6.17. Pharmacy Market for Dermatological Disorders in New Zealand, till 2035
      • 18.1.6.18. Pharmacy Market for Genetic Disorders in New Zealand, till 2035
      • 18.1.6.19. Pharmacy Market for Other Disorders in New Zealand, till 2035
    • 18.1.7. Pharmacy Market in Rest of Asia-Pacific, till 2035
      • 18.1.7.1. Pharmacy Market for Retail Pharmacy in Rest of Asia-Pacific, till 2035
      • 18.1.7.2. Pharmacy Market for e-pharmacy in Rest of Asia-Pacific, till 2035
      • 18.1.7.3. Pharmacy Market for Hospital Pharmacy in Rest of Asia-Pacific, till 2035
      • 18.1.7.4. Pharmacy Market for Other Pharmacies in Rest of Asia-Pacific, till 2035
      • 18.1.7.5. Pharmacy Market for Drugs / Pharmaceuticals in Rest of Asia-Pacific, till 2035
      • 18.1.7.6. Pharmacy Market for Medical Devices in Rest of Asia-Pacific, till 2035
      • 18.1.7.7. Pharmacy Market for Other Pharmacy Products in Rest of Asia-Pacific, till 2035
      • 18.1.7.8. Pharmacy Market for Prescription Products in Rest of Asia-Pacific, till 2035
      • 18.1.7.9. Pharmacy Market for Over-the-counter Products in Rest of Asia-Pacific, till 2035
      • 18.1.7.10. Pharmacy Market for Oncological Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.11. Pharmacy Market for Metabolic Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.13. Pharmacy Market for Respiratory Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.14. Pharmacy Market for Infectious Diseases in Rest of Asia-Pacific, till 2035
      • 18.1.7.15. Pharmacy Market for Cardiovascular Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.16. Pharmacy Market for Neurological Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.17. Pharmacy Market for Dermatological Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.18. Pharmacy Market for Genetic Disorders in Rest of Asia-Pacific, till 2035
      • 18.1.7.19. Pharmacy Market for Other Disorders in Rest of Asia-Pacific, till 2035

19. PHARMACY MARKET IN MIDDLE EAST AND NORTH AFRICA

  • 19.1. Pharmacy Market in Middle East and North Africa, till 2035
    • 19.1.1. Pharmacy Market in Egypt, till 2035
      • 19.1.1.1. Pharmacy Market for Retail Pharmacy in Egypt, till 2035
      • 19.1.1.2. Pharmacy Market for e-pharmacy in Egypt, till 2035
      • 19.1.1.3. Pharmacy Market for Hospital Pharmacy in Egypt, till 2035
      • 19.1.1.4. Pharmacy Market for Other Pharmacies in Egypt, till 2035
      • 19.1.1.5. Pharmacy Market for Drugs / Pharmaceuticals in Egypt, till 2035
      • 19.1.1.6. Pharmacy Market for Medical Devices in Egypt, till 2035
      • 19.1.1.7. Pharmacy Market for Other Pharmacy Products in Egypt, till 2035
      • 19.1.1.8. Pharmacy Market for Prescription Products in Egypt, till 2035
      • 19.1.1.9. Pharmacy Market for Over-the-counter Products in Egypt, till 2035
      • 19.1.1.10. Pharmacy Market for Oncological Disorders in Egypt, till 2035
      • 19.1.1.11. Pharmacy Market for Metabolic Disorders in Egypt, till 2035
      • 19.1.1.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Egypt, till 2035
      • 19.1.1.13. Pharmacy Market for Respiratory Disorders in Egypt, till 2035
      • 19.1.1.14. Pharmacy Market for Infectious Diseases in Egypt, till 2035
      • 19.1.1.15. Pharmacy Market for Cardiovascular Disorders in Egypt, till 2035
      • 19.1.1.16. Pharmacy Market for Neurological Disorders in Egypt, till 2035
      • 19.1.1.17. Pharmacy Market for Dermatological Disorders in Egypt, till 2035
      • 19.1.1.18. Pharmacy Market for Genetic Disorders in Egypt, till 2035
      • 19.1.1.19 Pharmacy Market for Other Disorders in Egypt, till 2035
    • 19.1.2. Pharmacy Market in Israel, till 2035
      • 19.1.2.1. Pharmacy Market for Retail Pharmacy in Israel, till 2035
      • 19.1.2.2. Pharmacy Market for e-pharmacy in Israel, till 2035
      • 19.1.2.3. Pharmacy Market for Hospital Pharmacy in Israel, till 2035
      • 19.1.2.4. Pharmacy Market for Other Pharmacies in Israel, till 2035
      • 19.1.2.5. Pharmacy Market for Drugs / Pharmaceuticals in Israel, till 2035
      • 19.1.2.6. Pharmacy Market for Medical Devices in Israel, till 2035
      • 19.1.2.7. Pharmacy Market for Other Pharmacy Products in Israel, till 2035
      • 19.1.2.8. Pharmacy Market for Prescription Products in Israel, till 2035
      • 19.1.2.9. Pharmacy Market for Over-the-counter Products in Israel, till 2035
      • 19.1.2.10. Pharmacy Market for Oncological Disorders in Israel, till 2035
      • 19.1.2.11. Pharmacy Market for Metabolic Disorders in Israel, till 2035
      • 19.1.2.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Israel, till 2035
      • 19.1.2.13. Pharmacy Market for Respiratory Disorders in Israel, till 2035
      • 19.1.2.14. Pharmacy Market for Infectious Diseases in Israel, till 2035
      • 19.1.2.15. Pharmacy Market for Cardiovascular Disorders in Israel, till 2035
      • 19.1.2.16. Pharmacy Market for Neurological Disorders in Israel, till 2035
      • 19.1.2.17. Pharmacy Market for Dermatological Disorders in Israel, till 2035
      • 19.1.2.18. Pharmacy Market for Genetic Disorders in Israel, till 2035
      • 19.1.2.19 Pharmacy Market for Other Disorders in Israel, till 2035
    • 19.1.3. Pharmacy Market in Saudi Arabia, till 2035
      • 19.1.3.1. Pharmacy Market for Retail Pharmacy in Saudi Arabia, till 2035
      • 19.1.3.2. Pharmacy Market for e-pharmacy in Saudi Arabia, till 2035
      • 19.1.3.3. Pharmacy Market for Hospital Pharmacy in Saudi Arabia, till 2035
      • 19.1.3.4. Pharmacy Market for Other Pharmacies in Saudi Arabia, till 2035
      • 19.1.3.5. Pharmacy Market for Drugs / Pharmaceuticals in Saudi Arabia, till 2035
      • 19.1.3.6. Pharmacy Market for Medical Devices in Saudi Arabia, till 2035
      • 19.1.3.7. Pharmacy Market for Other Pharmacy Products in Saudi Arabia, till 2035
      • 19.1.3.8. Pharmacy Market for Prescription Products in Saudi Arabia, till 2035
      • 19.1.3.9. Pharmacy Market for Over-the-counter Products in Saudi Arabia, till 2035
      • 19.1.3.10. Pharmacy Market for Oncological Disorders in Saudi Arabia, till 2035
      • 19.1.3.11. Pharmacy Market for Metabolic Disorders in Saudi Arabia, till 2035
      • 19.1.3.12. Pharmacy Market for Autoimmune / Inflammatory Disorders in Saudi Arabia, till 2035
      • 19.1.3.13. Pharmacy Market for Respiratory Disorders in Saudi Arabia, till 2035
      • 19.1.3.14. Pharmacy Market for Infectious Diseases in Saudi Arabia, till 2035
      • 19.1.3.15. Pharmacy Market for Cardiovascular Disorders in Saudi Arabia, till 2035
      • 19.1.3.16. Pharmacy Market for Neurological Disorders in Saudi Arabia, till 2035
      • 19.1.3.17. Pharmacy Market for Dermatological Disorders in Saudi Arabia, till 2035
      • 19.1.3.18. Pharmacy Market for Genetic Disorders in Saudi Arabia, till 2035
      • 19.1.3.19 Pharmacy Market for Other Disorders in Saudi Arabia, till 2035
    • 19.1.4. Ph

List of Tables

  • Table 22.1 Pharmacy Players: List of Key Companies
  • Table 23.1 A.S. Watson: Service Portfolio
  • Table 23.2 Cigna: Service Portfolio
  • Table 23.3 CVS Health: Service Portfolio
  • Table 23.4 Dr. Max: Service Portfolio
  • Table 23.5 Kroger: Service Portfolio
  • Table 23.6 Matsumoto Kiyoshi: Service Portfolio
  • Table 23.7 Phoenix: Service Portfolio
  • Table 23.8 Rite Aid: Service Portfolio
  • Table 23.9 Walgreens Boots Alliance: Service Portfolio
  • Table 23.10 Well Pharmacy: Service Portfolio
  • Table 24.1 Ahold Delhaize: Service Portfolio
  • Table 24.2 Albertsons: Service Portfolio
  • Table 24.3 Cardinal Health: Service Portfolio
  • Table 24.4 Cosmos Pharmaceutical: Service Portfolio
  • Table 24.5 Costco: Service Portfolio
  • Table 24.6 Dirk Rossmann: Service Portfolio
  • Table 24.7 Good Neighbor Pharmacy: Service Portfolio
  • Table 24.8 Health Mart: Service Portfolio
  • Table 24.9 Optum: Service Portfolio
  • Table 24.10 The Jean Coutu: Service Portfolio
  • Table 24.11 Walmart: Service Portfolio
  • Table 28.1 Global Pharmacy Market, till 2035 (USD Trillion)
  • Table 28.2 Global Pharmacy Market: Conservative Scenario, till 2035 (USD Trillion)
  • Table 28.3 Global Pharmacy Market: t, Optimistic Scenario, till 2035 (USD Trillion)
  • Table 28.4 Pharmacy Market, Distribution by Type of Pharmacy, 2019, 2024 and 2035
  • Table 28.5 Pharmacy Market for Retail Pharmacy, till 2035 (USD Billion)
  • Table 28.6 Pharmacy Market for e-pharmacy, till 2035 (USD Billion)
  • Table 28.7 Pharmacy Market for Hospital Pharmacy, till 2035 (USD Billion)
  • Table 28.8 Pharmacy Market for Other Pharmacies, till 2035 (USD Billion)
  • Table 28.9 Pharmacy Market, Distribution by Type of Product, 2019, 2024 and 2035
  • Table 28.10 Pharmacy Market for Drugs / Pharmaceuticals, till 2035 (USD Billion)
  • Table 28.11 Pharmacy Market for Medical Devices, till 2035 (USD Billion)
  • Table 28.12 Pharmacy Market for Other Pharmacy Products, till 2035 (USD Billion)
  • Table 28.13 Pharmacy Market, Distribution by Availability, 2019, 2024 and 2035
  • Table 28.14 Pharmacy Market for Prescription Products, till 2035 (USD Billion)
  • Table 28.15 Pharmacy Market for Over-the-counter Products, till 2035 (USD Billion)
  • Table 28.16 Pharmacy Market, Distribution by Type of Drug, 2019, 2024 and 2035
  • Table 28.17 Pharmacy Market for Branded / Patented Drugs, till 2035 (USD Billion)
  • Table 28.18 Pharmacy Market for Generic Drugs, till 2035 (USD Billion)
  • Table 28.19 Pharmacy Market, Distribution by Drug Molecule, 2019, 2024 and 2035
  • Table 28.20 Pharmacy Market for Small Molecules, till 2035 (USD Billion)
  • Table 28.21 Pharmacy Market for Biologics, till 2035 (USD Billion)
  • Table 28.22 Pharmacy Market, Distribution by e-pharmacy Platform, 2019, 2024 and 2035
  • Table 28.23 Pharmacy Market for App-based Platform, till 2035 (USD Billion)
  • Table 28.24 Pharmacy Market for Web-based Platform, till 2035 (USD Billion)
  • Table 28.25 Pharmacy Market, Distribution by Therapeutic Area, 2019, 2024 and 2035
  • Table 28.26 Pharmacy Market for Oncological Disorders, till 2035 (USD Billion)
  • Table 28.27 Pharmacy Market for Metabolic Disorders, till 2035 (USD Billion)
  • Table 28.28 Pharmacy Market for Autoimmune / Inflammatory Disorders, till 2035 (USD Billion)
  • Table 28.29 Pharmacy Market for Respiratory Disorders, till 2035 (USD Billion)
  • Table 28.30 Pharmacy Market for Infectious Diseases, till 2035 (USD Billion)
  • Table 28.31 Pharmacy Market for Cardiovascular Disorders, till 2035 (USD Billion)
  • Table 28.32 Pharmacy Market for Neurological Disorders, till 2035 (USD Billion)
  • Table 28.33 Pharmacy Market for Dermatological Disorders, till 2035 (USD Billion)
  • Table 28.34 Pharmacy Market for Genetic Disorders, till 2035 (USD Billion)
  • Table 28.35 Pharmacy Market for Other Disorders, till 2035 (USD Billion)
  • Table 28.36 Pharmacy Market, Distribution by Geographical Regions, 2019, 2024 and 2035
  • Table 28.37 Pharmacy Market in North America, till 2035 (USD Billion)
  • Table 28.38 Pharmacy Market in the US, till 2035 (USD Billion)
  • Table 28.39 Pharmacy Market in Canada, till 2035 (USD Billion)
  • Table 28.40 Pharmacy Market in Rest of North America, till 2035 (USD Billion)
  • Table 28.41 Pharmacy Market in Europe, till 2035 (USD Billion)
  • Table 28.42 Pharmacy Market in Germany, till 2035 (USD Billion)
  • Table 28.43 Pharmacy Market in France, till 2035 (USD Billion)
  • Table 28.44 Pharmacy Market in Italy, till 2035 (USD Billion)
  • Table 28.45 Pharmacy Market in the UK, till 2035 (USD Billion)
  • Table 28.46 Pharmacy Market in Spain, till 2035 (USD Billion)
  • Table 28.47 Pharmacy Market in Rest of Europe, till 2035 (USD Billion)
  • Table 28.48 Pharmacy Market in Asia-Pacific, till 2035 (USD Billion)
  • Table 28.49 Pharmacy Market in Japan, till 2035 (USD Billion)
  • Table 28.50 Pharmacy Market in China, till 2035 (USD Billion)
  • Table 28.51 Pharmacy Market in India, till 2035 (USD Billion)
  • Table 28.52 Pharmacy Market in Korea, till 2035 (USD Billion)
  • Table 28.53 Pharmacy Market in Australia, till 2035 (USD Billion)
  • Table 28.54 Pharmacy Market in New Zealand, till 2035 (USD Billion)
  • Table 28.55 Pharmacy Market in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Table 28.56 Pharmacy Market in Middle East and North Africa, till 2035 (USD Billion)
  • Table 28.57 Pharmacy Market in Egypt, till 2035 (USD Billion)
  • Table 28.58 Pharmacy Market in Israel, till 2035 (USD Billion)
  • Table 28.59 Pharmacy Market in Saudi Arabia, till 2035 (USD Billion)
  • Table 28.60 Pharmacy Market in Rest of Middle East and North Arica, till 2035 (USD Billion)
  • Table 28.61 Pharmacy Market in Latin America, till 2035 (USD Billion)
  • Table 28.62 Pharmacy Market in Brazil, till 2035 (USD Billion)
  • Table 28.63 Pharmacy Market in Rest of Latin America, till 2035 (USD Billion)
  • Table 28.64 Distribution by Year of Establishment
  • Table 28.65 Distribution by Company Size
  • Table 28.66 Distribution by Company Ownership
  • Table 28.67 Distribution by Location of Headquarters
  • Table 28.68 A.S. Watson: Financial Information (HKD Billion)
  • Table 28.69 Cigna: Financial Information (USD Billion)
  • Table 28.70 CVS Health: Financial Information (USD Billion)
  • Table 28.71 Dr. Max: Financial Information (EUR Billion)
  • Table 28.72 Kroger: Financial Information (USD Billion)
  • Table 28.73 Matsumoto Kiyoshi: Financial Information (JPY Billion)
  • Table 28.74 Phoenix: Financial Information (EUR Billion)
  • Table 28.75 Rite Aid: Financial Information (USD Billion)
  • Table 28.76 Walgreens Boots Alliance: Financial Information (USD Billion)
  • Table 28.77 Bestway (parent company of Well Pharmacy): Financial Information (USD Billion)

List of Figures

  • Figure 5.1 Key Regulatory Authorities
  • Figure 5.2 Technological Advancements in Pharmacy Industry
  • Figure 6.1 Market Drivers
  • Figure 6.2 Market Restraints
  • Figure 6.3 Market Opportunities
  • Figure 6.4 Market Challenges
  • Figure 7.1 Global Pharmacy Market, till 2035 (USD Trillion)
  • Figure 7.2 Global Pharmacy Market: Conservative Scenario, till 2035 (USD Trillion)
  • Figure 7.3 Global Pharmacy Market: t, Optimistic Scenario, till 2035 (USD Trillion)
  • Figure 8.1 Pharmacy Market, Distribution by Type of Pharmacy, 2019, 2024 and 2035
  • Figure 8.2 Pharmacy Market for Retail Pharmacy, till 2035 (USD Billion)
  • Figure 8.3 Pharmacy Market for e-pharmacy, till 2035 (USD Billion)
  • Figure 8.4 Pharmacy Market for Hospital Pharmacy, till 2035 (USD Billion)
  • Figure 8.5 Pharmacy Market for Other Pharmacies, till 2035 (USD Billion)
  • Figure 9.1 Pharmacy Market, Distribution by Type of Product, 2019, 2024 and 2035
  • Figure 9.2 Pharmacy Market for Drugs / Pharmaceuticals, till 2035 (USD Billion)
  • Figure 9.3 Pharmacy Market for Medical Devices, till 2035 (USD Billion)
  • Figure 9.4 Pharmacy Market for Other Pharmacy Products, till 2035 (USD Billion)
  • Figure 10.1 Pharmacy Market, Distribution by Availability, 2019, 2024 and 2035
  • Figure 10.2 Pharmacy Market for Prescription Products, till 2035 (USD Billion)
  • Figure 10.3 Pharmacy Market for Over-the-counter Products, till 2035 (USD Billion)
  • Figure 11.1 Pharmacy Market, Distribution by Type of Drug, 2019, 2024 and 2035
  • Figure 11.2 Pharmacy Market for Branded / Patented Drugs, till 2035 (USD Billion)
  • Figure 11.3 Pharmacy Market for Generic Drugs, till 2035 (USD Billion)
  • Figure 12.1 Pharmacy Market, Distribution by Drug Molecule, 2019, 2024 and 2035
  • Figure 12.2 Pharmacy Market for Small Molecules, till 2035 (USD Billion)
  • Figure 12.3 Pharmacy Market for Biologics, till 2035 (USD Billion)
  • Figure 13.1 Pharmacy Market, Distribution by e-pharmacy Platforms, 2019, 2024 and 2035
  • Figure 13.2 Pharmacy Market for App-based Platforms, till 2035 (USD Billion)
  • Figure 13.3 Pharmacy Market for Web-based Platforms, till 2035 (USD Billion)
  • Figure 14.1 Pharmacy Market, Distribution by Therapeutic Area, 2019, 2024 and 2035
  • Figure 14.2 Pharmacy Market for Oncological Disorders, till 2035 (USD Billion)
  • Figure 14.3 Pharmacy Market for Metabolic Disorders, till 2035 (USD Billion)
  • Figure 14.4 Pharmacy Market for Autoimmune / Inflammatory Disorders, till 2035 (USD Billion)
  • Figure 14.5 Pharmacy Market for Respiratory Disorders, till 2035 (USD Billion)
  • Figure 14.6 Pharmacy Market for Infectious Diseases, till 2035 (USD Billion)
  • Figure 14.7 Pharmacy Market for Cardiovascular Disorders, till 2035 (USD Billion)
  • Figure 14.8 Pharmacy Market for Neurological Disorders, till 2035 (USD Billion)
  • Figure 14.9 Pharmacy Market for Dermatological Disorders, till 2035 (USD Billion)
  • Figure 14.10 Pharmacy Market for Genetic Disorders, till 2035 (USD Billion)
  • Figure 14.11 Pharmacy Market for Other Disorders, till 2035 (USD Billion)
  • Figure 15.1 Pharmacy Market, Distribution by Geographical Regions, 2019, 2024 and 2035
  • Figure 16.1 Pharmacy Market in North America, till 2035 (USD Billion)
  • Figure 16.2 Pharmacy Market in the US, till 2035 (USD Billion)
  • Figure 16.3 Pharmacy Market for Retail Pharmacy in the US, till 2035 (USD Billion)
  • Figure 16.4 Pharmacy Market for e-pharmacy in the US, till 2035 (USD Billion)
  • Figure 16.5 Pharmacy Market for Hospital Pharmacy in the US, till 2035 (USD Billion)
  • Figure 16.6 Pharmacy Market for Other Pharmacies in the US, till 2035 (USD Billion)
  • Figure 16.7 Pharmacy Market for Drugs / Pharmaceuticals in the US, till 2035 (USD Billion)
  • Figure 16.8 Pharmacy Market for Medical Devices in the US, till 2035 (USD Billion)
  • Figure 16.9 Pharmacy Market for Other Pharmacy Products in the US, till 2035 (USD Billion)
  • Figure 16.10 Pharmacy Market for Prescription Products in the US, till 2035 (USD Billion)
  • Figure 16.11 Pharmacy Market for Over-the-counter Products in the US, till 2035 (USD Billion)
  • Figure 16.12 Pharmacy Market for Oncological Disorders in the US, till 2035 (USD Billion)
  • Figure 16.13 Pharmacy Market for Metabolic Disorders in the US, till 2035 (USD Billion)
  • Figure 16.14 Pharmacy Market for Autoimmune / Inflammatory Disorders in the US, till 2035 (USD Billion)
  • Figure 16.15 Pharmacy Market for Respiratory Disorders in the US, till 2035 (USD Billion)
  • Figure 16.16 Pharmacy Market for Infectious Diseases in the US, till 2035 (USD Billion)
  • Figure 16.17 Pharmacy Market for Cardiovascular Disorders in the US, till 2035 (USD Billion)
  • Figure 16.18 Pharmacy Market for Neurological Disorders in the US, till 2035 (USD Billion)
  • Figure 16.19 Pharmacy Market for Dermatological Disorders in the US, till 2035 (USD Billion)
  • Figure 16.20 Pharmacy Market for Genetic Disorders in the US, till 2035 (USD Billion)
  • Figure 16.21 Pharmacy Market for Other Disorders in the US, till 2035 (USD Billion)
  • Figure 16.22 Pharmacy Market in Canada, till 2035 (USD Billion)
  • Figure 16.23 Pharmacy Market for Retail Pharmacy in Canada, till 2035 (USD Billion)
  • Figure 16.24 Pharmacy Market for e-pharmacy in Canada, till 2035 (USD Billion)
  • Figure 16.25 Pharmacy Market for Hospital Pharmacy in Canada, till 2035 (USD Billion)
  • Figure 16.26 Pharmacy Market for Other Pharmacies in Canada, till 2035 (USD Billion)
  • Figure 16.27 Pharmacy Market for Drugs / Pharmaceuticals in Canada, till 2035 (USD Billion)
  • Figure 16.28 Pharmacy Market for Medical Devices in Canada, till 2035 (USD Billion)
  • Figure 16.29 Pharmacy Market for Other Pharmacy Products in Canada, till 2035 (USD Billion)
  • Figure 16.30 Pharmacy Market for Prescription Products in Canada, till 2035 (USD Billion)
  • Figure 16.31 Pharmacy Market for Over-the-counter Products in Canada, till 2035 (USD Billion)
  • Figure 16.32 Pharmacy Market for Oncological Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.33 Pharmacy Market for Metabolic Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.34 Pharmacy Market for Autoimmune / Inflammatory Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.35 Pharmacy Market for Respiratory Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.36 Pharmacy Market for Infectious Diseases in Canada, till 2035 (USD Billion)
  • Figure 16.37 Pharmacy Market for Cardiovascular Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.38 Pharmacy Market for Neurological Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.39 Pharmacy Market for Dermatological Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.40 Pharmacy Market for Genetic Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.41 Pharmacy Market for Other Disorders in Canada, till 2035 (USD Billion)
  • Figure 16.42 Pharmacy Market in Rest of North America, till 2035 (USD Billion)
  • Figure 16.43 Pharmacy Market for Retail Pharmacy in Rest of North America, till 2035 (USD Billion)
  • Figure 16.44 Pharmacy Market for e-pharmacy in Rest of North America, till 2035 (USD Billion)
  • Figure 16.45 Pharmacy Market for Hospital Pharmacy in Rest of North America, till 2035 (USD Billion)
  • Figure 16.46 Pharmacy Market for Other Pharmacies in Rest of North America, till 2035 (USD Billion)
  • Figure 16.47 Pharmacy Market for Drugs / Pharmaceuticals in Rest of North America, till 2035 (USD Billion)
  • Figure 16.48 Pharmacy Market for Medical Devices in Rest of North America, till 2035 (USD Billion)
  • Figure 16.49 Pharmacy Market for Other Pharmacy Products in Rest of North America, till 2035 (USD Billion)
  • Figure 16.50 Pharmacy Market for Prescription Products in Rest of North America, till 2035 (USD Billion)
  • Figure 16.51 Pharmacy Market for Over-the-counter Products in Rest of North America, till 2035 (USD Billion)
  • Figure 16.52 Pharmacy Market for Oncological Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.53 Pharmacy Market for Metabolic Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.54 Pharmacy Market for Autoimmune / Inflammatory Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.55 Pharmacy Market for Respiratory Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.56 Pharmacy Market for Infectious Diseases in Rest of North America, till 2035 (USD Billion)
  • Figure 16.57 Pharmacy Market for Cardiovascular Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.58 Pharmacy Market for Neurological Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.59 Pharmacy Market for Dermatological Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.60 Pharmacy Market for Genetic Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 16.61 Pharmacy Market for Other Disorders in Rest of North America, till 2035 (USD Billion)
  • Figure 17.1 Pharmacy Market in Europe, till 2035 (USD Billion)
  • Figure 17.2 Pharmacy Market in Germany, till 2035 (USD Billion)
  • Figure 17.3 Pharmacy Market for Retail Pharmacy in Germany, till 2035 (USD Billion)
  • Figure 17.4 Pharmacy Market for e-pharmacy in Germany, till 2035 (USD Billion)
  • Figure 17.5 Pharmacy Market for Hospital Pharmacy in Germany, till 2035 (USD Billion)
  • Figure 17.6 Pharmacy Market for Other Pharmacies in Germany, till 2035 (USD Billion)
  • Figure 17.7 Pharmacy Market for Drugs / Pharmaceuticals in Germany, till 2035 (USD Billion)
  • Figure 17.8 Pharmacy Market for Medical Devices in Germany, till 2035 (USD Billion)
  • Figure 17.9 Pharmacy Market for Other Pharmacy Products in Germany, till 2035 (USD Billion)
  • Figure 17.10 Pharmacy Market for Prescription Products in Germany, till 2035 (USD Billion)
  • Figure 17.11 Pharmacy Market for Over-the-counter Products in Germany, till 2035 (USD Billion)
  • Figure 17.12 Pharmacy Market for Oncological Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.13 Pharmacy Market for Metabolic Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.14 Pharmacy Market for Autoimmune / Inflammatory Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.15 Pharmacy Market for Respiratory Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.16 Pharmacy Market for Infectious Diseases in Germany, till 2035 (USD Billion)
  • Figure 17.17 Pharmacy Market for Cardiovascular Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.18 Pharmacy Market for Neurological Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.19 Pharmacy Market for Dermatological Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.20 Pharmacy Market for Genetic Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.21 Pharmacy Market for Other Disorders in Germany, till 2035 (USD Billion)
  • Figure 17.22 Pharmacy Market in France, till 2035 (USD Billion)
  • Figure 17.23 Pharmacy Market for Retail Pharmacy in France, till 2035 (USD Billion)
  • Figure 17.24 Pharmacy Market for e-pharmacy in France, till 2035 (USD Billion)
  • Figure 17.25 Pharmacy Market for Hospital Pharmacy in France, till 2035 (USD Billion)
  • Figure 17.26 Pharmacy Market for Other Pharmacies in France, till 2035 (USD Billion)
  • Figure 17.27 Pharmacy Market for Drugs / Pharmaceuticals in France, till 2035 (USD Billion)
  • Figure 17.28 Pharmacy Market for Medical Devices in France, till 2035 (USD Billion)
  • Figure 17.29 Pharmacy Market for Other Pharmacy Products in France, till 2035 (USD Billion)
  • Figure 17.30 Pharmacy Market for Prescription Products in France, till 2035 (USD Billion)
  • Figure 17.31 Pharmacy Market for Over-the-counter Products in France, till 2035 (USD Billion)
  • Figure 17.32 Pharmacy Market for Oncological Disorders in France, till 2035 (USD Billion)
  • Figure 17.33 Pharmacy Market for Metabolic Disorders in France, till 2035 (USD Billion)
  • Figure 17.34 Pharmacy Market for Autoimmune / Inflammatory Disorders in France, till 2035 (USD Billion)
  • Figure 17.35 Pharmacy Market for Respiratory Disorders in France, till 2035 (USD Billion)
  • Figure 17.36 Pharmacy Market for Infectious Diseases in France, till 2035 (USD Billion)
  • Figure 17.37 Pharmacy Market for Cardiovascular Disorders in France, till 2035 (USD Billion)
  • Figure 17.38 Pharmacy Market for Neurological Disorders in France, till 2035 (USD Billion)
  • Figure 17.39 Pharmacy Market for Dermatological Disorders in France, till 2035 (USD Billion)
  • Figure 17.40 Pharmacy Market for Genetic Disorders in France, till 2035 (USD Billion)
  • Figure 17.41 Pharmacy Market for Other Disorders in France, till 2035 (USD Billion)
  • Figure 17.42 Pharmacy Market in Italy, till 2035 (USD Billion)
  • Figure 17.43 Pharmacy Market for Retail Pharmacy in Italy, till 2035 (USD Billion)
  • Figure 17.44 Pharmacy Market for e-pharmacy in Italy, till 2035 (USD Billion)
  • Figure 17.45 Pharmacy Market for Hospital Pharmacy in Italy, till 2035 (USD Billion)
  • Figure 17.46 Pharmacy Market for Other Pharmacies in Italy, till 2035 (USD Billion)
  • Figure 17.47 Pharmacy Market for Drugs / Pharmaceuticals in Italy, till 2035 (USD Billion)
  • Figure 17.48 Pharmacy Market for Medical Devices in Italy, till 2035 (USD Billion)
  • Figure 17.49 Pharmacy Market for Other Pharmacy Products in Italy, till 2035 (USD Billion)
  • Figure 17.50 Pharmacy Market for Prescription Products in Italy, till 2035 (USD Billion)
  • Figure 17.51 Pharmacy Market for Over-the-counter Products in Italy, till 2035 (USD Billion)
  • Figure 17.52 Pharmacy Market for Oncological Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.53 Pharmacy Market for Metabolic Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.54 Pharmacy Market for Autoimmune / Inflammatory Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.55 Pharmacy Market for Respiratory Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.56 Pharmacy Market for Infectious Diseases in Italy, till 2035 (USD Billion)
  • Figure 17.57 Pharmacy Market for Cardiovascular Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.58 Pharmacy Market for Neurological Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.59 Pharmacy Market for Dermatological Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.60 Pharmacy Market for Genetic Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.61 Pharmacy Market for Other Disorders in Italy, till 2035 (USD Billion)
  • Figure 17.62 Pharmacy Market in the UK, till 2035 (USD Billion)
  • Figure 17.63 Pharmacy Market for Retail Pharmacy in the UK, till 2035 (USD Billion)
  • Figure 17.64 Pharmacy Market for e-pharmacy in the UK, till 2035 (USD Billion)
  • Figure 17.65 Pharmacy Market for Hospital Pharmacy in the UK, till 2035 (USD Billion)
  • Figure 17.66 Pharmacy Market for Other Pharmacies in the UK, till 2035 (USD Billion)
  • Figure 17.67 Pharmacy Market for Drugs / Pharmaceuticals in the UK, till 2035 (USD Billion)
  • Figure 17.68 Pharmacy Market for Medical Devices in the UK, till 2035 (USD Billion)
  • Figure 17.69 Pharmacy Market for Other Pharmacy Products in the UK, till 2035 (USD Billion)
  • Figure 17.70 Pharmacy Market for Prescription Products in the UK, till 2035 (USD Billion)
  • Figure 17.71 Pharmacy Market for Over-the-counter Products in the UK, till 2035 (USD Billion)
  • Figure 17.72 Pharmacy Market for Oncological Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.73 Pharmacy Market for Metabolic Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.74 Pharmacy Market for Autoimmune / Inflammatory Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.75 Pharmacy Market for Respiratory Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.76 Pharmacy Market for Infectious Diseases in the UK, till 2035 (USD Billion)
  • Figure 17.77 Pharmacy Market for Cardiovascular Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.78 Pharmacy Market for Neurological Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.79 Pharmacy Market for Dermatological Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.80 Pharmacy Market for Genetic Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.81 Pharmacy Market for Other Disorders in the UK, till 2035 (USD Billion)
  • Figure 17.82 Pharmacy Market in Spain, till 2035 (USD Billion)
  • Figure 17.83 Pharmacy Market for Retail Pharmacy in Spain, till 2035 (USD Billion)
  • Figure 17.84 Pharmacy Market for e-pharmacy in Spain, till 2035 (USD Billion)
  • Figure 17.85 Pharmacy Market for Hospital Pharmacy in Spain, till 2035 (USD Billion)
  • Figure 17.86 Pharmacy Market for Other Pharmacies in Spain, till 2035 (USD Billion)
  • Figure 17.87 Pharmacy Market for Drugs / Pharmaceuticals in Spain, till 2035 (USD Billion)
  • Figure 17.88 Pharmacy Market for Medical Devices in Spain, till 2035 (USD Billion)
  • Figure 17.89 Pharmacy Market for Other Pharmacy Products in Spain, till 2035 (USD Billion)
  • Figure 17.90 Pharmacy Market for Prescription Products in Spain, till 2035 (USD Billion)
  • Figure 17.91 Pharmacy Market for Over-the-counter Products in Spain, till 2035 (USD Billion)
  • Figure 17.92 Pharmacy Market for Oncological Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.93 Pharmacy Market for Metabolic Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.94 Pharmacy Market for Autoimmune / Inflammatory Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.95 Pharmacy Market for Respiratory Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.96 Pharmacy Market for Infectious Diseases in Spain, till 2035 (USD Billion)
  • Figure 17.97 Pharmacy Market for Cardiovascular Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.98 Pharmacy Market for Neurological Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.99 Pharmacy Market for Dermatological Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.100 Pharmacy Market for Genetic Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.101 Pharmacy Market for Other Disorders in Spain, till 2035 (USD Billion)
  • Figure 17.102 Pharmacy Market in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.103 Pharmacy Market for Retail Pharmacy in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.104 Pharmacy Market for e-pharmacy in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.105 Pharmacy Market for Hospital Pharmacy in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.106 Pharmacy Market for Other Pharmacies in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.107 Pharmacy Market for Drugs / Pharmaceuticals in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.108 Pharmacy Market for Medical Devices in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.109 Pharmacy Market for Other Pharmacy Products in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.110 Pharmacy Market for Prescription Products in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.111 Pharmacy Market for Over-the-counter Products in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.112 Pharmacy Market for Oncological Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.113 Pharmacy Market for Metabolic Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.114 Pharmacy Market for Autoimmune / Inflammatory Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.115 Pharmacy Market for Respiratory Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.116 Pharmacy Market for Infectious Diseases in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.117 Pharmacy Market for Cardiovascular Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.118 Pharmacy Market for Neurological Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.119 Pharmacy Market for Dermatological Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.120 Pharmacy Market for Genetic Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 17.121 Pharmacy Market for Other Disorders in Rest of Europe, till 2035 (USD Billion)
  • Figure 18.1 Pharmacy Market in Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.2 Pharmacy Market in Japan, till 2035 (USD Billion)
  • Figure 18.3 Pharmacy Market for Retail Pharmacy in Japan, till 2035 (USD Billion)
  • Figure 18.4 Pharmacy Market for e-pharmacy in Japan, till 2035 (USD Billion)
  • Figure 18.5 Pharmacy Market for Hospital Pharmacy in Japan, till 2035 (USD Billion)
  • Figure 18.6 Pharmacy Market for Other Pharmacies in Japan, till 2035 (USD Billion)
  • Figure 18.7 Pharmacy Market for Drugs / Pharmaceuticals in Japan, till 2035 (USD Billion)
  • Figure 18.8 Pharmacy Market for Medical Devices in Japan, till 2035 (USD Billion)
  • Figure 18.9 Pharmacy Market for Other Pharmacy Products in Japan, till 2035 (USD Billion)
  • Figure 18.10 Pharmacy Market for Prescription Products in Japan, till 2035 (USD Billion)
  • Figure 18.11 Pharmacy Market for Over-the-counter Products in Japan, till 2035 (USD Billion)
  • Figure 18.12 Pharmacy Market for Oncological Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.13 Pharmacy Market for Metabolic Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.14 Pharmacy Market for Autoimmune / Inflammatory Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.15 Pharmacy Market for Respiratory Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.16 Pharmacy Market for Infectious Diseases in Japan, till 2035 (USD Billion)
  • Figure 18.17 Pharmacy Market for Cardiovascular Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.18 Pharmacy Market for Neurological Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.19 Pharmacy Market for Dermatological Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.20 Pharmacy Market for Genetic Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.21 Pharmacy Market for Other Disorders in Japan, till 2035 (USD Billion)
  • Figure 18.22 Pharmacy Market in China, till 2035 (USD Billion)
  • Figure 18.23 Pharmacy Market for Retail Pharmacy in China, till 2035 (USD Billion)
  • Figure 18.24 Pharmacy Market for e-pharmacy in China, till 2035 (USD Billion)
  • Figure 18.25 Pharmacy Market for Hospital Pharmacy in China, till 2035 (USD Billion)
  • Figure 18.26 Pharmacy Market for Other Pharmacies in China, till 2035 (USD Billion)
  • Figure 18.27 Pharmacy Market for Drugs / Pharmaceuticals in China, till 2035 (USD Billion)
  • Figure 18.28 Pharmacy Market for Medical Devices in China, till 2035 (USD Billion)
  • Figure 18.29 Pharmacy Market for Other Pharmacy Products in China, till 2035 (USD Billion)
  • Figure 18.30 Pharmacy Market for Prescription Products in China, till 2035 (USD Billion)
  • Figure 18.31 Pharmacy Market for Over-the-counter Products in China, till 2035 (USD Billion)
  • Figure 18.32 Pharmacy Market for Oncological Disorders in China, till 2035 (USD Billion)
  • Figure 18.33 Pharmacy Market for Metabolic Disorders in China, till 2035 (USD Billion)
  • Figure 18.34 Pharmacy Market for Autoimmune / Inflammatory Disorders in China, till 2035 (USD Billion)
  • Figure 18.35 Pharmacy Market for Respiratory Disorders in China, till 2035 (USD Billion)
  • Figure 18.36 Pharmacy Market for Infectious Diseases in China, till 2035 (USD Billion)
  • Figure 18.37 Pharmacy Market for Cardiovascular Disorders in China, till 2035 (USD Billion)
  • Figure 18.38 Pharmacy Market for Neurological Disorders in China, till 2035 (USD Billion)
  • Figure 18.39 Pharmacy Market for Dermatological Disorders in China, till 2035 (USD Billion)
  • Figure 18.40 Pharmacy Market for Genetic Disorders in China, till 2035 (USD Billion)
  • Figure 18.41 Pharmacy Market for Other Disorders in China, till 2035 (USD Billion)
  • Figure 18.42 Pharmacy Market in India, till 2035 (USD Billion)
  • Figure 18.43 Pharmacy Market for Retail Pharmacy in India, till 2035 (USD Billion)
  • Figure 18.44 Pharmacy Market for e-pharmacy in India, till 2035 (USD Billion)
  • Figure 18.45 Pharmacy Market for Hospital Pharmacy in India, till 2035 (USD Billion)
  • Figure 18.46 Pharmacy Market for Other Pharmacies in India, till 2035 (USD Billion)
  • Figure 18.47 Pharmacy Market for Drugs / Pharmaceuticals in India, till 2035 (USD Billion)
  • Figure 18.48 Pharmacy Market for Medical Devices in India, till 2035 (USD Billion)
  • Figure 18.49 Pharmacy Market for Other Pharmacy Products in India, till 2035 (USD Billion)
  • Figure 18.50 Pharmacy Market for Prescription Products in India, till 2035 (USD Billion)
  • Figure 18.51 Pharmacy Market for Over-the-counter Products in India, till 2035 (USD Billion)
  • Figure 18.52 Pharmacy Market for Oncological Disorders in India, till 2035 (USD Billion)
  • Figure 18.53 Pharmacy Market for Metabolic Disorders in India, till 2035 (USD Billion)
  • Figure 18.54 Pharmacy Market for Autoimmune / Inflammatory Disorders in India, till 2035 (USD Billion)
  • Figure 18.55 Pharmacy Market for Respiratory Disorders in India, till 2035 (USD Billion)
  • Figure 18.56 Pharmacy Market for Infectious Diseases in India, till 2035 (USD Billion)
  • Figure 18.57 Pharmacy Market for Cardiovascular Disorders in India, till 2035 (USD Billion)
  • Figure 18.58 Pharmacy Market for Neurological Disorders in India, till 2035 (USD Billion)
  • Figure 18.59 Pharmacy Market for Dermatological Disorders in India, till 2035 (USD Billion)
  • Figure 18.60 Pharmacy Market for Genetic Disorders in India, till 2035 (USD Billion)
  • Figure 18.61 Pharmacy Market for Other Disorders in India, till 2035 (USD Billion)
  • Figure 18.62 Pharmacy Market in Korea, till 2035 (USD Billion)
  • Figure 18.63 Pharmacy Market for Retail Pharmacy in Korea, till 2035 (USD Billion)
  • Figure 18.64 Pharmacy Market for e-pharmacy in Korea, till 2035 (USD Billion)
  • Figure 18.65 Pharmacy Market for Hospital Pharmacy in Korea, till 2035 (USD Billion)
  • Figure 18.66 Pharmacy Market for Other Pharmacies in Korea, till 2035 (USD Billion)
  • Figure 18.67 Pharmacy Market for Drugs / Pharmaceuticals in Korea, till 2035 (USD Billion)
  • Figure 18.68 Pharmacy Market for Medical Devices in Korea, till 2035 (USD Billion)
  • Figure 18.69 Pharmacy Market for Other Pharmacy Products in Korea, till 2035 (USD Billion)
  • Figure 18.70 Pharmacy Market for Prescription Products in Korea, till 2035 (USD Billion)
  • Figure 18.71 Pharmacy Market for Over-the-counter Products in Korea, till 2035 (USD Billion)
  • Figure 18.72 Pharmacy Market for Oncological Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.73 Pharmacy Market for Metabolic Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.74 Pharmacy Market for Autoimmune / Inflammatory Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.75 Pharmacy Market for Respiratory Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.76 Pharmacy Market for Infectious Diseases in Korea, till 2035 (USD Billion)
  • Figure 18.77 Pharmacy Market for Cardiovascular Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.78 Pharmacy Market for Neurological Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.79 Pharmacy Market for Dermatological Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.80 Pharmacy Market for Genetic Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.81 Pharmacy Market for Other Disorders in Korea, till 2035 (USD Billion)
  • Figure 18.82 Pharmacy Market in Australia, till 2035 (USD Billion)
  • Figure 18.83 Pharmacy Market for Retail Pharmacy in Australia, till 2035 (USD Billion)
  • Figure 18.84 Pharmacy Market for e-pharmacy in Australia, till 2035 (USD Billion)
  • Figure 18.85 Pharmacy Market for Hospital Pharmacy in Australia, till 2035 (USD Billion)
  • Figure 18.86 Pharmacy Market for Other Pharmacies in Australia, till 2035 (USD Billion)
  • Figure 18.87 Pharmacy Market for Drugs / Pharmaceuticals in Australia, till 2035 (USD Billion)
  • Figure 18.88 Pharmacy Market for Medical Devices in Australia, till 2035 (USD Billion)
  • Figure 18.89 Pharmacy Market for Other Pharmacy Products in Australia, till 2035 (USD Billion)
  • Figure 18.90 Pharmacy Market for Prescription Products in Australia, till 2035 (USD Billion)
  • Figure 18.91 Pharmacy Market for Over-the-counter Products in Australia, till 2035 (USD Billion)
  • Figure 18.92 Pharmacy Market for Oncological Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.93 Pharmacy Market for Metabolic Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.94 Pharmacy Market for Autoimmune / Inflammatory Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.95 Pharmacy Market for Respiratory Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.96 Pharmacy Market for Infectious Diseases in Australia, till 2035 (USD Billion)
  • Figure 18.97 Pharmacy Market for Cardiovascular Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.98 Pharmacy Market for Neurological Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.99 Pharmacy Market for Dermatological Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.100 Pharmacy Market for Genetic Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.101 Pharmacy Market for Other Disorders in Australia, till 2035 (USD Billion)
  • Figure 18.102 Pharmacy Market in New Zealand, till 2035 (USD Billion)
  • Figure 18.103 Pharmacy Market for Retail Pharmacy in New Zealand, till 2035 (USD Billion)
  • Figure 18.104 Pharmacy Market for e-pharmacy in New Zealand, till 2035 (USD Billion)
  • Figure 18.105 Pharmacy Market for Hospital Pharmacy in New Zealand, till 2035 (USD Billion)
  • Figure 18.106 Pharmacy Market for Other Pharmacies in New Zealand, till 2035 (USD Billion)
  • Figure 18.107 Pharmacy Market for Drugs / Pharmaceuticals in New Zealand, till 2035 (USD Billion)
  • Figure 18.108 Pharmacy Market for Medical Devices in New Zealand, till 2035 (USD Billion)
  • Figure 18.109 Pharmacy Market for Other Pharmacy Products in New Zealand, till 2035 (USD Billion)
  • Figure 18.110 Pharmacy Market for Prescription Products in New Zealand, till 2035 (USD Billion)
  • Figure 18.111 Pharmacy Market for Over-the-counter Products in New Zealand, till 2035 (USD Billion)
  • Figure 18.112 Pharmacy Market for Oncological Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.113 Pharmacy Market for Metabolic Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.114 Pharmacy Market for Autoimmune / Inflammatory Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.115 Pharmacy Market for Respiratory Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.116 Pharmacy Market for Infectious Diseases in New Zealand, till 2035 (USD Billion)
  • Figure 18.117 Pharmacy Market for Cardiovascular Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.118 Pharmacy Market for Neurological Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.119 Pharmacy Market for Dermatological Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.120 Pharmacy Market for Genetic Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.121 Pharmacy Market for Other Disorders in New Zealand, till 2035 (USD Billion)
  • Figure 18.122 Pharmacy Market in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.123 Pharmacy Market for Retail Pharmacy in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.124 Pharmacy Market for e-pharmacy in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.125 Pharmacy Market for Hospital Pharmacy in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.126 Pharmacy Market for Other Pharmacies in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.127 Pharmacy Market for Drugs / Pharmaceuticals in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.128 Pharmacy Market for Medical Devices in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.129 Pharmacy Market for Other Pharmacy Products in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.130 Pharmacy Market for Prescription Products in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.131 Pharmacy Market for Over-the-counter Products in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.132 Pharmacy Market for Oncological Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.133 Pharmacy Market for Metabolic Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.134 Pharmacy Market for Autoimmune / Inflammatory Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.135 Pharmacy Market for Respiratory Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.136 Pharmacy Market for Infectious Diseases in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.137 Pharmacy Market for Cardiovascular Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.138 Pharmacy Market for Neurological Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.139 Pharmacy Market for Dermatological Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.140 Pharmacy Market for Genetic Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 18.141 Pharmacy Market for Other Disorders in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 19.1 Pharmacy Market in Middle East and North Africa, till 2035 (USD Billion)
  • Figure 19.2 Pharmacy Market in Egypt, till 2035 (USD Billion)
  • Figure 19.3 Pharmacy Market for Retail Pharmacy in Egypt, till 2035 (USD Billion)
  • Figure 19.4 Pharmacy Market for e-pharmacy in Egypt, till 2035 (USD Billion)
  • Figure 19.5 Pharmacy Market for Hospital Pharmacy in Egypt, till 2035 (USD Billion)
  • Figure 19.6 Pharmacy Market for Other Pharmacies in Egypt, till 2035 (USD Billion)
  • Figure 19.7 Pharmacy Market for Drugs / Pharmaceuticals in Egypt, till 2035 (USD Billion)

Figure 19.